http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112618546-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02839ed514749f635038586b1846c6b5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9146a2a4f88ae960659f06bdba34a6a5 |
| publicationDate | 2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112618546-A |
| titleOfInvention | Application of PAD4 inhibitors in the preparation of radiotherapy sensitizing drugs |
| abstract | The present invention provides an application of a PAD4 inhibitor in the preparation of a radiotherapy sensitizing drug. Preferably, the PAD4 inhibitor is GSK484. The experimental results of the present invention confirm that by using the PAD4 inhibitor-GSK484 to act on nasopharyngeal carcinoma tumor cells, it can inhibit the mTOR signaling pathway, thereby inhibiting the proliferation of tumor cells. PAD4 regulates the activity of p21, thereby affecting the mTOR signaling pathway, Ultimately increase the sensitivity of nasopharyngeal carcinoma tumor cells to radiation. |
| priorityDate | 2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.